Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Teveten
Synonyms :
eprosartan
Class :
Angiotensin receptor blockers (ARBs)
Dosage forms & StrengthsÂ
TabletÂ
Indicated for Hypertension
Initial Dose:600mg orally every day
Maintenance Dose:400-800mg orally every day or in divided doses two times a day.
Renal Impairment
The patient should be carefully monitored. The maximum daily dosage should not exceed 600 mg
Hepatic Impairment
The patient should be carefully monitored. The maximum daily dosage should not exceed 600 mg
safety and efficacy not established.Â
Refer to adult dosing.Â
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may increase the adverse/toxic effect of angiotensin ii receptor blockers
may increase the adverse/toxic effect of angiotensin ii receptor blockers
may increase the hyperkalemic effect of aliskiren
may increase the adverse effect of angiotensin II receptor blockers
may enhance the serum concentration of angiotensin II receptor blockers
may increase the hyperkalemic effect of aliskiren
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
lithium: they may enhance the serum concentration of Angiotensin II Receptor antagonist
may increase the adverse effect of angiotensin II receptor blockers
may enhance the serum concentration of angiotensin ii receptor blockers
may enhance the serum concentration of angiotensin ii receptor blockers
it increases the toxicity of angiotensin II receptor blockers
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
may diminish the therapeutic effect of angiotensin II Receptor Blockers
may diminish the therapeutic effect of angiotensin II Receptor Blockers
may enhance the risk of adverse/toxic effect of NSAIDs
may enhance the risk of adverse/toxic effect of NSAIDs
may enhance the risk of adverse/toxic effect of NSAIDs
may enhance the risk of adverse/toxic effect of NSAIDs
may enhance the risk of adverse/toxic effect of NSAIDs
It may enhance the effects when combined with maitake by pharmacodynamic synergism
spironolactone and hydrochlorothiazide
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may have an increasingly adverse effect when combined with NSAIDs
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increasingly adverse effect when combined with NSAIDs
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of finerenone
may decrease the levels of serum potassium
it increases the effect of hyperkalemia of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
angiotensin II receptor blockers increase the toxicity of NSAIDs
angiotensin II receptor blockers increase the toxicity of NSAIDs
angiotensin II receptor blockers increase the toxicity of NSAIDs
angiotensin II receptor blockers increase the toxicity of NSAIDs
angiotensin II receptor blockers increase the toxicity of NSAIDs
it increases the toxicity of angiotensin II receptor blockers
it enhances the serum potassium levels
it enhances the serum potassium levels
may enhance the effects of the other by pharmacodynamic synergism
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may increase the orthostatic hypotensive effect of dapoxetine
may decrease the therapeutic effect of angiotensin-converting enzyme inhibitors
valsartan/hydrochlorothiazideÂ
may decreases the therapeutic effect. Angiotensin receptor
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the hyperkalemic effect when combined with angiotensin II receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
drospirenone/ethinyl estradiol/levomefolateÂ
may increase the hyperkalemic effect of Drospirenone-Containing Products
polyethylene glycol and electrolytesÂ
It may increase the nephrotoxic effect when combined with polyethylene Glycol-electrolyte Solution
eplerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonist
finerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
nicorandil: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
ranolazine: they may increase the toxic effect of Angiotensin II Receptor Blockers
tacrolimus: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
trimethoprim: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin II Receptor antagonist
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin II Receptor antagonist
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin II Receptor antagonist
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin II Receptor antagonist
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin II Receptor antagonist
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased hyperkalemic effect when combined with angiotensin II receptor blockers
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
the serum levels of potassium may be increased
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
Actions and Spectrum:Â
eprosartan is a medication that belongs to the class of drugs,angiotensin II receptor blockers (ARBs).
Its main action is to block the binding of angiotensin II to its receptors, which causes blood vessels to narrow and the release of hormones that increase blood pressure. By blocking this action, eprosartan helps to widen blood vessels, lower blood pressure, and improve blood flow.Â
In terms of its spectrum of activity, eprosartan is primarily used for treatment, hypertension (high blood pressure) in adults. It may also be used to help prevent complications related to high blood pressure, such as heart attack and stroke.Â
Frequency definedÂ
1-10%Â
Frequency not definedÂ
Black Box Warning:Â
eprosartan does not have a black box warning. However, like other medications in its class (ARBs), eprosartan may increase the risk of fetal injury or death if taken during pregnancy.
Therefore, it is important for women of childbearing age to use effective contraception while taking eprosartan and to discuss their options with their healthcare provider.Â
Contraindication/Caution:Â
ContraindicationÂ
CautionÂ
Pregnancy consideration:Â
Pregnancy Category:Â
C -1st trimesterÂ
D -2nd and 3rd trimesters.Â
During the 2nd and 3rd trimesters of the pregnancy period, these drugs have been linked with fetal injury that involves anuria, hypotension,reversible or irreversible renal failure, neonatal skull hypoplasia and deathÂ
Pregnancy category:Â
Pharmacology:Â
eprosartan is an angiotensin II receptor blocker (ARB) medication that works by selectively blocking the binding of AT-II to AT-I receptor, which is found on many cells in the body, including those in blood vessels, heart, kidneys, and adrenal gland.Â
By blocking the AT1 receptor, eprosartan prevents the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and a reduction in blood pressure. This action also leads to a decrease in sodium and water reabsorption by the kidneys, which can further contribute to a reduction in blood pressure.Â
Pharmacodynamics:Â
Mechanism of Action:Â
eprosartan is Angiotensin II blocker that works by displacing angiotensin II from the AT1 receptor. This process may lower blood pressure by counteracting AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release,
water absorption, and hypertrophic responses. It may lead to a more comprehensive inhibition of the renin-angiotensin system compared to ACE inhibitors, and it does not affect the response to bradykinin. Additionally, it inhibits the pressor effects of an angiotensin II infusion in a dose-dependent manner.Â
Pharmacokinetics:Â
AbsorptionÂ
The half-life of this medication is between 5 to 9 hours. It takes approximately 4 hours for the medication to take effect, and the peak plasma concentration is also reached around 4 hours after administration. The bioavailability of the medication is 13%, which can be increased by consuming food or with age.Â
DistributionÂ
eprosartan is highly protein-bound, with approximately 98% of the drug bound to protein molecules. The volume of distribution (Vd) of the medication is 3.8 LÂ
MetabolismÂ
eprosartan undergoes partial conjugation with glucuronic acid in the liver during metabolism. The primary metabolite produced as a result is an acyl glucuronide metabolite, which is inactive.Â
Elimination and ExcretionÂ
eprosartan is primarily eliminated through feces, with approximately 90% of the drug being excreted in this manner. A small amount of the medication (around 7%) is eliminated through urine.Â
The total body clearance of the medication is 48.5 L/hr, indicating that the drug is cleared relatively quickly from the body. The renal clearance of the medication is between 39 to 45 mL/minÂ
Administration:Â
Oral administrationÂ
eprosartan is typically administered orally in the form of tablets. The recommended dosage can be changed depending on condition being treated, age and other factors. It is generally recommended to take eprosartan with or without food once daily, at around the same time each day.Â
It is essential to follow the prescribing healthcare provider’s instructions carefully when taking this medication. Do not stop taking the medication abruptly without consulting a healthcare provider, as this could cause a sudden increase in blood pressure.Â
If a dose is missed, it is recommended to take it as soon as possible, unless it is almost time for the next scheduled dose, in which case it is advisable to skip the missed dose and resume with the regular dosing schedule.Â
Patient information leafletÂ
Generic Name: eprosartanÂ
Pronounced: [ ep-roe-SAR-tan ]Â
Why do we use eprosartan?Â
eprosartan is an angiotensin II receptor blocker (ARB) medication that is primarily used for the treatment of hypertension (high blood pressure) in adults. It works by blocking the action of AT- II, a hormone that can cause blood vessels to narrow, which can lead to high blood pressure.Â
In addition to hypertension, eprosartan may also be used in the management of other cardiovascular conditions, such as heart failure and diabetic nephropathy (kidney disease due to diabetes). However, the use of eprosartan in these conditions may vary depending on the patient’s specific situation and other medications they are taking.Â